TPEx voided the TPEx trading agreement for the given securities signed with Handa Pharmaceuticals, Inc. and returned its application for a TPEx primary listing to the Review[...]

According to the approval of TPEx's Board and Supervisor Joint Meeting, TPEx voided the TPEx trading agreement for the given securities signed with Handa Pharmaceuticals, Inc. (stock code: 6620, referred to as " Handa Pharma" hereunder) and returned its application for a TPEx primary listing to the Review Committee for re-review. Besides, Handa Pharma is found to have information and material information that requires reporting and announcement under Article 33 and 34 of the "Taipei Exchange Rules Governing the Review of Emerging Stocks for Trading on the TPEx" (referred to as "Emerging Stock Review Rules" hereunder), but failed to do so before the specified deadline. Hence TPEx imposed a penalty of NT$500,000 in accordance with the Emerging Stock Review Rules.